Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 76

    1.

    Correlation between gene expression of IGF-1R pathway markers and cetuximab benefit in metastatic colorectal cancer.

    Huang F, Xu LA, Khambata-Ford S.

    Clin Cancer Res. 2012 Feb 15;18(4):1156-66. Epub 2012 Jan 31.

    PMID:
    22294722
    [PubMed - in process]
    2.

    Relationship between 18F-fluorodeoxyglucose accumulation and KRAS/BRAF mutations in colorectal cancer.

    Kawada K, Nakamoto Y, Kawada M, Hida K, Matsumoto T, Murakami T, Hasegawa S, Togashi K, Sakai Y.

    Clin Cancer Res. 2012 Mar 15;18(6):1696-703. Epub 2012 Jan 26.

    PMID:
    22282467
    [PubMed - in process]
    3.

    Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan.

    Spindler KL, Pallisgaard N, Vogelius I, Jakobsen A.

    Clin Cancer Res. 2012 Feb 15;18(4):1177-85. Epub 2012 Jan 6.

    PMID:
    22228631
    [PubMed - in process]
    4.

    Increasing potential of HER3 signaling in colon cancer progression and therapy.

    Gespach C.

    Clin Cancer Res. 2012 Feb 15;18(4):917-9. Epub 2011 Dec 28.

    PMID:
    22205688
    [PubMed - in process]
    5.

    MiR-1 downregulation cooperates with MACC1 in promoting MET overexpression in human colon cancer.

    Migliore C, Martin V, Leoni VP, Restivo A, Atzori L, Petrelli A, Isella C, Zorcolo L, Sarotto I, Casula G, Comoglio PM, Columbano A, Giordano S.

    Clin Cancer Res. 2012 Feb 1;18(3):737-47. Epub 2011 Dec 16.

    PMID:
    22179665
    [PubMed - indexed for MEDLINE]
    6.

    Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models.

    Morelli MP, Tentler JJ, Kulikowski GN, Tan AC, Bradshaw-Pierce EL, Pitts TM, Brown AM, Nallapareddy S, Arcaroli JJ, Serkova NJ, Hidalgo M, Ciardiello F, Eckhardt SG.

    Clin Cancer Res. 2012 Feb 15;18(4):1051-62. Epub 2011 Dec 15.

    PMID:
    22173548
    [PubMed - in process]
    7.

    Clinical effects of adjuvant active specific immunotherapy differ between patients with microsatellite-stable and microsatellite-instable colon cancer.

    de Weger VA, Turksma AW, Voorham QJ, Euler Z, Bril H, van den Eertwegh AJ, Bloemena E, Pinedo HM, Vermorken JB, van Tinteren H, Meijer GA, Hooijberg E.

    Clin Cancer Res. 2012 Feb 1;18(3):882-9. Epub 2011 Dec 12.

    PMID:
    22156611
    [PubMed - indexed for MEDLINE]
    8.

    Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.

    Ogino S, Shima K, Meyerhardt JA, McCleary NJ, Ng K, Hollis D, Saltz LB, Mayer RJ, Schaefer P, Whittom R, Hantel A, Benson AB 3rd, Spiegelman D, Goldberg RM, Bertagnolli MM, Fuchs CS.

    Clin Cancer Res. 2012 Feb 1;18(3):890-900. Epub 2011 Dec 6.

    PMID:
    22147942
    [PubMed - indexed for MEDLINE]
    9.

    Toward the prognostic significance and therapeutic potential of HER3 receptor tyrosine kinase in human colon cancer.

    Beji A, Horst D, Engel J, Kirchner T, Ullrich A.

    Clin Cancer Res. 2012 Feb 15;18(4):956-68. Epub 2011 Dec 5.

    PMID:
    22142822
    [PubMed - in process]
    10.

    Overexpression of ZEB2 at the invasion front of colorectal cancer is an independent prognostic marker and regulates tumor invasion in vitro.

    Kahlert C, Lahes S, Radhakrishnan P, Dutta S, Mogler C, Herpel E, Brand K, Steinert G, Schneider M, Mollenhauer M, Reissfelder C, Klupp F, Fritzmann J, Wunder C, Benner A, Kloor M, Huth C, Contin P, Ulrich A, Koch M, Weitz J.

    Clin Cancer Res. 2011 Dec 15;17(24):7654-63. Epub 2011 Oct 31.

    PMID:
    22042972
    [PubMed - in process]
    11.

    Micromanaging the classification of colon cancer: the role of the microRNAome.

    Vilar E, Tabernero J, Gruber SB.

    Clin Cancer Res. 2011 Dec 1;17(23):7207-9. Epub 2011 Oct 21.

    PMID:
    22019515
    [PubMed - indexed for MEDLINE]
    12.

    Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.

    Zaanan A, Fléjou JF, Emile JF, Des GG, Cuilliere-Dartigues P, Malka D, Lecaille C, Validire P, Louvet C, Rougier P, de Gramont A, Bonnetain F, Praz F, Taïeb J.

    Clin Cancer Res. 2011 Dec 1;17(23):7470-8. Epub 2011 Oct 13.

    PMID:
    21998335
    [PubMed - indexed for MEDLINE]
    13.

    A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer.

    Smits KM, Paranjape T, Nallur S, Wouters KA, Weijenberg MP, Schouten LJ, van den Brandt PA, Bosman FT, Weidhaas JB, van Engeland M.

    Clin Cancer Res. 2011 Dec 15;17(24):7723-31. Epub 2011 Oct 12.

    PMID:
    21994416
    [PubMed - in process]
    14.

    Genetic variation in inflammatory pathways is related to colorectal cancer survival.

    Coghill AE, Newcomb PA, Poole EM, Hutter CM, Makar KW, Duggan D, Potter JD, Ulrich CM.

    Clin Cancer Res. 2011 Nov 15;17(22):7139-47. Epub 2011 Oct 5.

    PMID:
    21976545
    [PubMed - indexed for MEDLINE]
    15.

    Colorectal cancers with microsatellite instability display unique miRNA profiles.

    Balaguer F, Moreira L, Lozano JJ, Link A, Ramirez G, Shen Y, Cuatrecasas M, Arnold M, Meltzer SJ, Syngal S, Stoffel E, Jover R, Llor X, Castells A, Boland CR, Gironella M, Goel A.

    Clin Cancer Res. 2011 Oct 1;17(19):6239-49. Epub 2011 Aug 15.

    PMID:
    21844009
    [PubMed - indexed for MEDLINE]
    16.

    Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients.

    Azzopardi N, Lecomte T, Ternant D, Boisdron-Celle M, Piller F, Morel A, Gouilleux-Gruart V, Vignault-Desvignes C, Watier H, Gamelin E, Paintaud G.

    Clin Cancer Res. 2011 Oct 1;17(19):6329-37. Epub 2011 Sep 27.

    PMID:
    21953502
    [PubMed - indexed for MEDLINE]
    17.

    Complex patterns of altered MicroRNA expression during the adenoma-adenocarcinoma sequence for microsatellite-stable colorectal cancer.

    Bartley AN, Yao H, Barkoh BA, Ivan C, Mishra BM, Rashid A, Calin GA, Luthra R, Hamilton SR.

    Clin Cancer Res. 2011 Dec 1;17(23):7283-93. Epub 2011 Sep 23.

    PMID:
    21948089
    [PubMed - indexed for MEDLINE]
    18.

    Common cancer stem cell gene variants predict colon cancer recurrence.

    Gerger A, Zhang W, Yang D, Bohanes P, Ning Y, Winder T, LaBonte MJ, Wilson PM, Benhaim L, Paez D, El-Khoueiry R, El-Khoueiry A, Kahn M, Lenz HJ.

    Clin Cancer Res. 2011 Nov 1;17(21):6934-43. Epub 2011 Sep 14.

    PMID:
    21918173
    [PubMed - indexed for MEDLINE]
    19.

    EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies.

    Poindessous V, Ouaret D, El Ouadrani K, Battistella A, Mégalophonos VF, Kamsu-Kom N, Petitprez A, Escargueil AE, Boudou P, Dumont S, Cervera P, Fléjou JF, André T, Tournigand C, Chibaudel B, de Gramont A, Larsen AK.

    Clin Cancer Res. 2011 Oct 15;17(20):6522-30. Epub 2011 Aug 31.

    PMID:
    21880790
    [PubMed - indexed for MEDLINE]
    20.

    KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective.

    Blank PR, Moch H, Szucs TD, Schwenkglenks M.

    Clin Cancer Res. 2011 Oct 1;17(19):6338-46. Epub 2011 Aug 1.

    PMID:
    21807639
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk